Treatment: cancer immunotherapy (anti-PD-1, anti-PD-L1, anti-CTLA-4)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Before the first infusion
Fasting laboratory tests, 10 to 15 days before the first infusion
- FBC with platelets
- Serum electrolytes
- Serum creatinine with eGFR
- Full liver function tests: AST
- ALT
- GGT
- Alkaline phosphatase
- Bilirubin
- Fasting plasma glucose
- TSH (free T4 as a reflex test if TSH abnormal)
- 8 am serum cortisol (away from any corticosteroid therapy)
- Troponin
- Creatine kinase (CK)
- NT-proBNP
- Lipid profile
- Hepatitis B serology (HBsAg, anti-HBc, anti-HBs)
- Hepatitis C serology
- HIV serology
- HbA1c
- Free T4 straight away with the TSH (anti-CTLA-4 or combination)if neededThe SFE asks for TSH and free T4 together at every check [2]; TNCD asks for free T4 only if TSH is abnormal [3]. Useful above all under anti-CTLA-4, where hypophysitis predominates [3]. Outside the reflex-test setting, not reimbursed in France unless a central cause is suspected [4].
- LH, FSH, testosterone (men); FSH (postmenopausal women)if neededRecommended by the SFE to screen for hypophysitis [2]; absent from the TNCD tests [3].
- Serum β-hCG (woman of childbearing potential)if neededWoman of childbearing potential [3].
Urine tests
- Urine protein:creatinine ratio (spot sample)
- Urine microscopy and culture
- Not a laboratory test: baseline ECG (copy given to the patient), chest imaging, oxygen saturation.
Do not order
During treatment (before each cycle)
Before each infusion
- FBC with platelets
- Serum electrolytes
- Serum creatinine with eGFR
- Full liver function tests: AST
- ALT
- GGT
- Alkaline phosphatase
- Bilirubin
- Urine protein:creatinine ratio (spot sample)
- Urine microscopy and culture
At each cycle for 6 months, then every 2 cycles
- Fasting plasma glucose
- TSH (free T4 as a reflex test if TSH abnormal)
- Free T4 straight away with the TSH (if anti-CTLA-4 or combination)if neededThe SFE [2], ASCO [9], the German S3 [5], SITC [6] and the ESE [7] measure free T4 with TSH; TNCD only if TSH is abnormal [3]. Hypophysitis, especially under anti-CTLA-4, may leave TSH normal or low [3,9]. Outside the reflex-test setting, not reimbursed in France unless a central cause is suspected [4].
- 8 am serum cortisol
- Testosterone (men)if neededRecommended by the SFE at every check for 6 months [2]; absent from TNCD follow-up [3].
During the first 4 cycles, then every 3 months
- Troponin (same laboratory as the baseline value)
- Not a laboratory test: ECG at the same frequency as troponin; examination of the skin and mucous membranes before each infusion.
Do not order
- Routine serum lipase or amylase during treatment in an asymptomatic patient: not recommended, unless pancreatitis is clinically suspected [9]
Fatigue, malaise or new symptom on immunotherapy
- Patient looks seriously ill: call the emergency medical service (SAMU); hydrocortisone without waiting for the cortisol result.
Laboratory tests the same day
- Plasma glucose
- Serum electrolytes (sodium, potassium)
- Serum cortisol, whatever the time (note the time and any corticosteroid intake)
- ACTH, on the same sample as the cortisol (if possible)if needednon-French guidelineDistinguishes primary adrenal insufficiency (high ACTH) from hypophysitis (low or normal ACTH); to be taken at the same time as cortisol, without delaying hydrocortisone [2,9].
- TSH (free T4 as a reflex test if TSH abnormal)
- Free T4 straight away with the TSH (write "suspected central hypothyroidism")if neededHeadache, severe fatigue, hyponatraemia or another sign of hypophysitis: TSH may remain normal or low despite thyrotroph deficiency, hence the free T4 measurement [2,9]. Covered by the French laboratory fee schedule (NABM) straight away if suspicion of a central cause is stated on the prescription (procedure 1211) [4].
- Serum creatinine with eGFR
- AST
- ALT
- GGT
- Alkaline phosphatase
- Bilirubin
- FBC with platelets
- Troponin, CK (chest pain, dyspnoea, palpitations, muscle weakness)if neededSuspected myocarditis or myositis: urgent specialist advice and suspension of immunotherapy [3].
- Stool culture, Clostridioides difficile testing (if diarrhoea)if neededAn infectious colitis must be ruled out before any corticosteroid therapy according to TNCD [3], SITC [6] and eviQ in Australia [11]. Sampling does not delay a treatment judged necessary [6].
- Serum lipase (if abdominal pain or vomiting)if needednon-French guidelineTo look for pancreatitis: SITC [6] and eviQ [11] reserve this test for symptoms, like ASCO [9]. An isolated rise without symptoms is not treated [11]; hence no routine measurement during treatment.
After stopping immunotherapy
At 1 month, 3 months and 6 months after stopping
- TSH (free T4 as a reflex test if TSH abnormal)
- 8 am serum cortisol
- AST
- ALT
- GGT
- Alkaline phosphatase
- Bilirubin
Every month for 6 months
- Urea
- Serum creatinine with eGFR
Between 6 and 12 months after stopping
- Troponin
- Not a laboratory test: ECG between 6 and 12 months after stopping.
Sources (11)
- Grumberg V, Cotté F-E, Giroux-Leprieur E, Gaudin A-F. Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021. ESMO Open 2024;9(2):102240.
- Castinetti F, Albarel F, Archambeaud F, et al. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer. 2019;26(2):G1-G18.
- Jary M, Coutzac C, Bonnet D, et al. Bilan pré-thérapeutique et surveillance des immunothérapies en oncologie digestive. Thésaurus national de cancérologie digestive (TNCD), chapitre 26, SNFGE, version du 24/11/2025.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1207 (T4 libre), 1208 (TSH), 1211 (TSH + T4 libre) et 1577 (HbA1c).
- Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen, Langversion 2.1, février 2026, chapitre 13 (effets immunomédiés des inhibiteurs de point de contrôle) (Allemagne).
- Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435.
- Husebye ES, Castinetti F, Criseno S, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022;187(6):G1-G21.
- Velindre University NHS Trust, Medicines Management Group. South East Wales Immunotherapy Toxicity Guidelines (v3), octobre 2022 (guide régional, pays de Galles, Royaume-Uni).
- Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714-1768 (mise à jour 2021 non lue).
- Higham CE, Olsson-Brown A, Carroll P, et al. Society for Endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect. 2018;7(7):G1-G7.
- Cancer Institute NSW, eviQ. Management of immune-related adverse events (irAEs), ID 1993 v.6, revue le 23 septembre 2026 (Australie).